Clostridium difficile (C. difficile) is a type of bacterium that lives in people’s guts. When this bacterium grows in number, it can cause an infection, C. difficile infection (CDI) that can be mild, moderate or severe. Occasionally, after initial treatment with antibiotics, the infection can re-occur, and the more times the infection re-occurs, the more likely is this to happen again. When infection happens for second and subsequent times, treatment options become more limited and less effective. Symptoms of CDI include watery diarrhoea, painful stomach cramps, dehydration, loss of appetite, weight loss.
RBX-2660 is a therapy under development for recurrent CDI. It is a non-antibiotic therapy that consists of human-derived microorganisms (microbiota suspension). It is administered directly into the patient’s intestine through the rectum as an enema. RBX-2660 has the potential to treat patients re-infected by C. difficile that currently have limited treatment options available and are at risk of serious health consequences.
Ibalizumab in combination with other antiretroviral(s) has been developed for the treatment of adults infected with multidrug-resistant HIV-1 (MDR HIV-1). HIV is a virus that damages the cells in the immune system and weakens the ability to fight everyday infections and diseases. HIV-1 is the most common type of HIV infection, which is incurable but there are effective treatments that enable most infected people to live a healthy life. Antiretroviral medicines are used to treat HIV. There are however limited effective treatments for some treatment-experienced patients with extensive MDR HIV-1.